Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
D000210:Acute-Phase Reaction / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018771:Arthralgia; D001798:Blood Proteins / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics; D005192:Family Health; D005260:Female; D005334:Fever; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008297:Male; D009154:Mutation; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D010375:Pedigree; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D013577:Syndrome; D014581:Urticaria / Q000188:drug therapy / Q000235:genetics / Q000473:pathology
D018501:Antirheumatic Agents; D001798:Blood Proteins; D002352:Carrier Proteins; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins